|Bid||21.20 x 1300|
|Ask||21.21 x 1200|
|Day's Range||20.67 - 21.48|
|52 Week Range||8.85 - 24.33|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Representing IVERIC Bio today are Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Keith Westby, chief operating officer; David Carroll, chief financial officer; Dr. Dhaval Desai, chief development officer; Chris Simms, chief commercial officer; and Tony Gibney, chief business and strategy officer. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
Investors are applauding the company's late-stage clinical results for its lead pipeline candidate.
IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.